Amgen inlicenses US rights for CHF drug from Servier

AMGN announced a deal with Servier (a privately held French pharma) to gain US rights to  Procoralan. Procoralan is an oral drug indicated for treatment of chronic heart failure and stable angina (chest pain). Amgen will pay $50mn upfront payment and future undisclosed milestones and royalties.